Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.
M. Sodhi,Ramin Rezaeianzadeh,Abbas Kezouh,M. Etminan
2023 · DOI: 10.1001/jama.2023.19574
286 Zitierungen
Abstract
This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.